Vyome Holdings (HIND) Amortization of Deferred Charges (2020 - 2021)
Vyome Holdings (HIND) posted quarterly Amortization of Deferred Charges of -$6000.0 for Q2 2021, down 101.2% quarter-over-quarter from $500000.0 in Q1 2021.
Vyome Holdings (HIND) Amortization of Deferred Charges (2020 - 2021) Analysis & Trends
Vyome Holdings' Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at -$6000.0 for Q2 2021.
- In Q2 2021, Amortization of Deferred Charges changed N/A year-over-year to -$6000.0; the TTM figure through Dec 2021 stood at $494000.0 (changed N/A YoY), while the FY2021 annual figure was $494000.0, up 114.78% from the prior year.
- Amortization of Deferred Charges for Q2 2021 stood at -$6000.0, down from $500000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $500000.0 in Q1 2021, with the low at -$6000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -6,000.00 |
| Jun 30, 2021 | -6,000.00 |
| Mar 31, 2021 | 500,000.00 |
| Mar 31, 2021 | 500,000.00 |
| Dec 31, 2020 | 55,000.00 |
| Dec 31, 2020 | 55,000.00 |
| Sep 30, 2020 | 58,000.00 |
| Sep 30, 2020 | 58,000.00 |